Bobby S. Korn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bobby S. Korn has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Don O. Kikkawa
Division of Oculofacial Plastic and Reconstructive Surgery, Viterbi Family Department of Ophthalmology, University of California, San Diego, Shiley Eye Institute
10 shared publicationsCatherine Y. Liu
Viterbi Family Department of Ophthalmology, Division of Oculofacial Plastic and Reconstructive Surgery, UC San Diego, La Jolla, CA
4 shared publicationsDaniel J. Ozzello
Viterbi Family Department of Ophthalmology, Division of Oculofacial Plastic and Reconstructive Surgery, UC San Diego, La Jolla, CA
4 shared publicationsZvi Gur
Department of Ophthalmology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem
3 shared publicationsCatherine Y. M.D. Liu
Division of Oculofacial Plastic and Reconstructive Surgery, Viterbi Family Department of Ophthalmology, UC San Diego Shiley Eye Institute, La Jolla, California, U.S.A.
2 shared publicationsClara J. Men
UC San Diego Shiley Eye Institute
2 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
Medical Literature-Specific Artificial Intelligence: Analyzing the performance of OpenEvidence, Heidi Evidence, Consensus, and PubMed.ai in the context of Lacrimal Drainage Disorders
Purpose: This study aimed to report the performance of medical literature-specific artificial intelligence (MLS-AI) deep learning tools in the context of lacrimal drainage disorders. Methods: Prompt engineering was performed using 22 previously validated questions and statements to include common and rare aspects of lacrimal drainage disorders. Prompts were presented at least twice to the latest versions of OpenEvidence, Heidi Evidence, Consensus, and PubMed.ai [Accessed May 14–26, 2026]. The prompts included general queries, such as the management of congenital nasolacrimal duct obstructions, as well as specific queries, such as the terminology of idiopathic canalicular inflammatory disease or a history of dacryocystorhinostomy surgery. The MLS-AI were also quizzed on controversial topics, such as the use of silicone intubation and mitomycin-C in dacryocystorhinostomy. The responses were assessed for overall quality, organization, and clarity, evidence-based content, updated knowledge, specific responses, speed, and factual inaccuracies. The responses were graded by the authors as correct, partially correct, and factually incorrect. Results: The overall performance of OpenEvidence and Heidi was comparable in the context of lacrimal drainage disorders. However, Heidi hallucinated twice, giving OpenEvidence an edge over Heidi. Consensus came in a close third largely due to the quality of its responses. There is much to be desired from the performance of PubMed.ai. In terms of response accuracy, the MLS-AI models performed differently. OpenEvidence’s responses were graded as correct in 90.9% (20/22), and partially correct in 9.1% (2/22), with no factually incorrect responses. Heidi’s responses were graded as correct in 63.6% (14/22), partially correct in 31.8% (7/22), and factually incorrect in 4.6% (1/22). In comparison, the responses of Consensus were graded as correct in 54.5% (12/22), partially correct in 40.9% (9/22), and factually incorrect in 4.6% (1/22). PubMed.ai was the worst-performing MLS-AI, with 45.5% partially correct responses, 22.7% (5/22) factually incorrect answers, and 9% (2/22) with no response. Conclusion: OpenEvidence has a slight edge over Heidi Evidence. PubMed.ai is lagging far behind the other 3 tools. Each of the MLS-AI tools had unique advantages and could complement one another based on context and prompt type. They need to be specifically trained further to capture more indexed mainstream journal publications. All MLS-AI responses at present should have human oversight and verification before they are accepted as true.
- 8 October 2026
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
Open AccessMedical Literature-Specific Artificial Intelligence: Analyzing the performance of OpenEvidence, Heidi Evidence, Consensus, and PubMed.ai in the context of Lacrimal Drainage Disorders
Purpose: This study aimed to report the performance of medical literature-specific artificial intelligence (MLS-AI) deep learning tools in the context of lacrimal drainage disorders. Methods: Prompt engineering was performed using 22 previously validated questions and statements to include common and rare aspects of lacrimal drainage disorders. Prompts were presented at least twice to the latest versions of OpenEvidence, Heidi Evidence, Consensus, and PubMed.ai [Accessed May 14–26, 2026]. The prompts included general queries, such as the management of congenital nasolacrimal duct obstructions, as well as specific queries, such as the terminology of idiopathic canalicular inflammatory disease or a history of dacryocystorhinostomy surgery. The MLS-AI were also quizzed on controversial topics, such as the use of silicone intubation and mitomycin-C in dacryocystorhinostomy. The responses were assessed for overall quality, organization, and clarity, evidence-based content, updated knowledge, specific responses, speed, and factual inaccuracies. The responses were graded by the authors as correct, partially correct, and factually incorrect. Results: The overall performance of OpenEvidence and Heidi was comparable in the context of lacrimal drainage disorders. However, Heidi hallucinated twice, giving OpenEvidence an edge over Heidi. Consensus came in a close third largely due to the quality of its responses. There is much to be desired from the performance of PubMed.ai. In terms of response accuracy, the MLS-AI models performed differently. OpenEvidence’s responses were graded as correct in 90.9% (20/22), and partially correct in 9.1% (2/22), with no factually incorrect responses. Heidi’s responses were graded as correct in 63.6% (14/22), partially correct in 31.8% (7/22), and factually incorrect in 4.6% (1/22). In comparison, the responses of Consensus were graded as correct in 54.5% (12/22), partially correct in 40.9% (9/22), and factually incorrect in 4.6% (1/22). PubMed.ai was the worst-performing MLS-AI, with 45.5% partially correct responses, 22.7% (5/22) factually incorrect answers, and 9% (2/22) with no response. Conclusion: OpenEvidence has a slight edge over Heidi Evidence. PubMed.ai is lagging far behind the other 3 tools. Each of the MLS-AI tools had unique advantages and could complement one another based on context and prompt type. They need to be specifically trained further to capture more indexed mainstream journal publications. All MLS-AI responses at present should have human oversight and verification before they are accepted as true.
- 24 September 2026
- Published by Wolters Kluwer Health in International Ophthalmology Clinics
- Vol. 66 (4) , 81-90
Clinical Trial Updates in Biological Treatment of Thyroid Eye Disease
Thyroid eye disease (TED) is the most common extrathyroidal manifestation of Graves' disease, causing proptosis, diplopia, and, in severe cases, vision loss. The 2020 approval of the first insulin-like growth factor 1 receptor (IGF-1R) inhibitor for TED introduced disease-specific pharmacotherapy and prompted accelerated development of additional biological agents across multiple mechanistic classes. This review summarizes the clinical trial evidence for biological agents currently approved or in late-stage development for TED, drawing on peer-reviewed publications, conference presentations, and sponsor disclosures through early 2026. Among the mechanistic classes evaluated, IGF-1R inhibition has accumulated the largest randomized trial evidence base. Multiple IGF-1R-directed agents, delivered by intravenous, subcutaneous, and oral routes, have demonstrated statistically significant reductions in proptosis in placebo-controlled trials, with responder rates that vary by agent, route, and disease activity. Interleukin-6 receptor (IL-6R) antagonism produced discordant Phase 3 primary endpoint outcomes across 2 parallel pivotal trials. Neonatal Fc receptor (FcRn) inhibition and selective interleukin-17A blockade each failed to meet primary endpoints in Phase 2 or Phase 3 studies. B-cell directed therapies and other off-label agents have produced inconsistent results in smaller, generally nonrandomized studies. In parallel, the use of orbital decompression has declined in the era following IGF-1R inhibitor approval, reflecting the changing role of surgery in pathways that initially lead with medical therapy. As comparative trial data emerge and the field moves toward treatment selection based on phenotype, clinicians will be better equipped to individualize biological therapy by disease stage, severity, safety profile, and patient preference.
- 24 September 2026
- Published by Wolters Kluwer Health in International Ophthalmology Clinics
- Vol. 66 (4) , 81-90
Clinical Trial Updates in Biological Treatment of Thyroid Eye Disease
Thyroid eye disease (TED) is the most common extrathyroidal manifestation of Graves' disease, causing proptosis, diplopia, and, in severe cases, vision loss. The 2020 approval of the first insulin-like growth factor 1 receptor (IGF-1R) inhibitor for TED introduced disease-specific pharmacotherapy and prompted accelerated development of additional biological agents across multiple mechanistic classes. This review summarizes the clinical trial evidence for biological agents currently approved or in late-stage development for TED, drawing on peer-reviewed publications, conference presentations, and sponsor disclosures through early 2026. Among the mechanistic classes evaluated, IGF-1R inhibition has accumulated the largest randomized trial evidence base. Multiple IGF-1R-directed agents, delivered by intravenous, subcutaneous, and oral routes, have demonstrated statistically significant reductions in proptosis in placebo-controlled trials, with responder rates that vary by agent, route, and disease activity. Interleukin-6 receptor (IL-6R) antagonism produced discordant Phase 3 primary endpoint outcomes across 2 parallel pivotal trials. Neonatal Fc receptor (FcRn) inhibition and selective interleukin-17A blockade each failed to meet primary endpoints in Phase 2 or Phase 3 studies. B-cell directed therapies and other off-label agents have produced inconsistent results in smaller, generally nonrandomized studies. In parallel, the use of orbital decompression has declined in the era following IGF-1R inhibitor approval, reflecting the changing role of surgery in pathways that initially lead with medical therapy. As comparative trial data emerge and the field moves toward treatment selection based on phenotype, clinicians will be better equipped to individualize biological therapy by disease stage, severity, safety profile, and patient preference.
- 23 September 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 281, 172-180
Outcomes of Frontalis Advancement With or Without External Levator Advancement for Congenital Ptosis: A Retrospective Comparative Study
- 23 September 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 281, 172-180
Outcomes of Frontalis Advancement With or Without External Levator Advancement for Congenital Ptosis: A Retrospective Comparative Study
- 29 April 2025
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 156 (5) , 725-729
Single-Stage Management of Recalcitrant Eyelid Festoons
Background: Lower eyelid festoons are a challenging aesthetic concern characterized by redundant and edematous folds of lower eyelid skin with minimal orbital fat prolapse. The authors present their surgical approach to managing this condition. Methods: A retrospective chart review was conducted on patients who underwent surgical repair of lower eyelid festoons at 2 academic centers. Data collected included various measurements, examinations, and satisfaction rates. The procedure involved lower eyelid tightening, an infraorbital curvilinear incision along the base of the lowest festoon, subcutaneous dissection, skin redraping, and closure with a running 7-0 Prolene suture. The orbital septum was kept intact with no orbital fat manipulation. Results: Fifty-four eyes of 27 patients (mean patient age, 69 ± 10 years) were studied, with a mean follow-up of 11 months. The average vertical extent of excised skin was 15 mm. No patient developed lagophthalmos, corneal staining, or eyelid retraction. Minor complications occurred in 2 patients. The recurrence rate was 3.7%. The patient and physician satisfaction rates were high. Conclusions: Direct infraorbital excision of festoons with concomitant preservation of the inferior tarsal orbicularis oculi muscle, lower eyelid tightening, and septal preservation is a simple and effective treatment option. More than 10 mm of skin can be excised safely without causing lower eyelid retraction. Outcomes are durable at a mean follow-up of nearly 1 year. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
- 29 April 2025
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 156 (5) , 725-729
Single-Stage Management of Recalcitrant Eyelid Festoons
Background: Lower eyelid festoons are a challenging aesthetic concern characterized by redundant and edematous folds of lower eyelid skin with minimal orbital fat prolapse. The authors present their surgical approach to managing this condition. Methods: A retrospective chart review was conducted on patients who underwent surgical repair of lower eyelid festoons at 2 academic centers. Data collected included various measurements, examinations, and satisfaction rates. The procedure involved lower eyelid tightening, an infraorbital curvilinear incision along the base of the lowest festoon, subcutaneous dissection, skin redraping, and closure with a running 7-0 Prolene suture. The orbital septum was kept intact with no orbital fat manipulation. Results: Fifty-four eyes of 27 patients (mean patient age, 69 ± 10 years) were studied, with a mean follow-up of 11 months. The average vertical extent of excised skin was 15 mm. No patient developed lagophthalmos, corneal staining, or eyelid retraction. Minor complications occurred in 2 patients. The recurrence rate was 3.7%. The patient and physician satisfaction rates were high. Conclusions: Direct infraorbital excision of festoons with concomitant preservation of the inferior tarsal orbicularis oculi muscle, lower eyelid tightening, and septal preservation is a simple and effective treatment option. More than 10 mm of skin can be excised safely without causing lower eyelid retraction. Outcomes are durable at a mean follow-up of nearly 1 year. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
- 22 February 2024
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 35 (4) , e325-e329
Reconstruction of Full-Thickness Eyelid Defects Following Tumor Resection: The Bucket Handle Modification
Purpose: To describe a modified approach for full-thickness lower eyelid defect reconstruction. Methods: This is a retrospective review of 5 patients with large full-thickness lower eyelid defects after tumor resection requiring reconstruction. For these lower eyelid defects, a lateral-based or superior-based tarsoconjunctival pedicle flap from the upper eyelid was used to rebuild the posterior lamella. In all cases, the anterior lamella was supplied from an adjacent myocutaneous flap in a bucket handle configuration. Data collection included tumor type and location, size of eyelid defect, presence of canalicular involvement, postoperative eyelid position, patient satisfaction, and complication rates. Results: Five eyelids of 5 patients underwent Mohs micrographic excision of basal cell carcinoma followed by reconstruction with a bucket handle flap. Age range was 68 to 96 years old (mean of 81 y). Five patients presented with lower eyelid involvement. The defect size ranged from 80% to 100% of the eyelid. Three patients had canalicular involvement and required bicanalicular nasolacrimal stent placement. After reconstruction, all patients showed good eyelid apposition to the globe with excellent esthetic outcome. No revision procedures were done. Average follow-up time was 13 months (range of 8 to 21 mo) Conclusion: The bucket handle flap for full-thickness eyelid reconstruction is a simple technique that allows for preservation of all anatomical layers of the anterior lamella. This technique shows promising functional and esthetic outcomes.
- 22 February 2024
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 35 (4) , e325-e329
Reconstruction of Full-Thickness Eyelid Defects Following Tumor Resection: The Bucket Handle Modification
Purpose: To describe a modified approach for full-thickness lower eyelid defect reconstruction. Methods: This is a retrospective review of 5 patients with large full-thickness lower eyelid defects after tumor resection requiring reconstruction. For these lower eyelid defects, a lateral-based or superior-based tarsoconjunctival pedicle flap from the upper eyelid was used to rebuild the posterior lamella. In all cases, the anterior lamella was supplied from an adjacent myocutaneous flap in a bucket handle configuration. Data collection included tumor type and location, size of eyelid defect, presence of canalicular involvement, postoperative eyelid position, patient satisfaction, and complication rates. Results: Five eyelids of 5 patients underwent Mohs micrographic excision of basal cell carcinoma followed by reconstruction with a bucket handle flap. Age range was 68 to 96 years old (mean of 81 y). Five patients presented with lower eyelid involvement. The defect size ranged from 80% to 100% of the eyelid. Three patients had canalicular involvement and required bicanalicular nasolacrimal stent placement. After reconstruction, all patients showed good eyelid apposition to the globe with excellent esthetic outcome. No revision procedures were done. Average follow-up time was 13 months (range of 8 to 21 mo) Conclusion: The bucket handle flap for full-thickness eyelid reconstruction is a simple technique that allows for preservation of all anatomical layers of the anterior lamella. This technique shows promising functional and esthetic outcomes.
- 12 January 2024
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 40 (3) , 303-311
Evaluating the Accuracy of ChatGPT and Google BARD in Fielding Oculoplastic Patient Queries: A Comparative Study on Artificial versus Human Intelligence
Purpose: This study evaluates and compares the accuracy of responses from 2 artificial intelligence platforms to patients’ oculoplastics-related questions. Methods: Questions directed toward oculoplastic surgeons were collected, rephrased, and input independently into ChatGPT-3.5 and BARD chatbots, using the prompt: “As an oculoplastic surgeon, how can I respond to my patient’s question?.” Responses were independently evaluated by 4 experienced oculoplastic specialists as comprehensive, correct but inadequate, mixed correct and incorrect/outdated data, and completely incorrect. Additionally, the empathy level, length, and automated readability index of the responses were assessed. Results: A total of 112 patient questions underwent evaluation. The rates of comprehensive, correct but inadequate, mixed, and completely incorrect answers for ChatGPT were 71.4%, 12.9%, 10.5%, and 5.1%, respectively, compared with 53.1%, 18.3%, 18.1%, and 10.5%, respectively, for BARD. ChatGPT showed more empathy (48.9%) than BARD (13.2%). All graders found that ChatGPT outperformed BARD in question categories of postoperative healing, medical eye conditions, and medications. Categorizing questions by anatomy, ChatGPT excelled in answering lacrimal questions (83.8%), while BARD performed best in the eyelid group (60.4%). ChatGPT’s answers were longer and potentially more challenging to comprehend than BARD’s. Conclusion: This study emphasizes the promising role of artificial intelligence-powered chatbots in oculoplastic patient education and support. With continued development, these chatbots may potentially assist physicians and offer patients accurate information, ultimately contributing to improved patient care while alleviating surgeon burnout. However, it is crucial to highlight that artificial intelligence may be good at answering questions, but physician oversight remains essential to ensure the highest standard of care and address complex medical cases.
- 12 January 2024
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 40 (3) , 303-311
Evaluating the Accuracy of ChatGPT and Google BARD in Fielding Oculoplastic Patient Queries: A Comparative Study on Artificial versus Human Intelligence
Purpose: This study evaluates and compares the accuracy of responses from 2 artificial intelligence platforms to patients’ oculoplastics-related questions. Methods: Questions directed toward oculoplastic surgeons were collected, rephrased, and input independently into ChatGPT-3.5 and BARD chatbots, using the prompt: “As an oculoplastic surgeon, how can I respond to my patient’s question?.” Responses were independently evaluated by 4 experienced oculoplastic specialists as comprehensive, correct but inadequate, mixed correct and incorrect/outdated data, and completely incorrect. Additionally, the empathy level, length, and automated readability index of the responses were assessed. Results: A total of 112 patient questions underwent evaluation. The rates of comprehensive, correct but inadequate, mixed, and completely incorrect answers for ChatGPT were 71.4%, 12.9%, 10.5%, and 5.1%, respectively, compared with 53.1%, 18.3%, 18.1%, and 10.5%, respectively, for BARD. ChatGPT showed more empathy (48.9%) than BARD (13.2%). All graders found that ChatGPT outperformed BARD in question categories of postoperative healing, medical eye conditions, and medications. Categorizing questions by anatomy, ChatGPT excelled in answering lacrimal questions (83.8%), while BARD performed best in the eyelid group (60.4%). ChatGPT’s answers were longer and potentially more challenging to comprehend than BARD’s. Conclusion: This study emphasizes the promising role of artificial intelligence-powered chatbots in oculoplastic patient education and support. With continued development, these chatbots may potentially assist physicians and offer patients accurate information, ultimately contributing to improved patient care while alleviating surgeon burnout. However, it is crucial to highlight that artificial intelligence may be good at answering questions, but physician oversight remains essential to ensure the highest standard of care and address complex medical cases.
- 26 February 2023
- Published by Elsevier in Facial Plastic Surgery Clinics of North America
- Vol. 31 (2) , 227-238
Reducing Surgical Risks in a Blepharoplasty
- 26 February 2023
- Published by Elsevier in Facial Plastic Surgery Clinics of North America
- Vol. 31 (2) , 227-238
Reducing Surgical Risks in a Blepharoplasty
- 9 September 2022
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 39 (1) , e15-e17
Conjunctival Perivascular Epithelioid Cell Neoplasm With RBM10-TFE3 Fusion Presenting as Recurrent Subconjunctival Hemorrhage
Subconjunctival hemorrhages commonly present to eye care professionals and are frequently regarded as benign self-limited conditions. In selected cases, subconjunctival hemorrhages can be a harbinger of more severe disease. Perivascular epithelioid cell tumors, or PEComas, are rare mesenchymal neoplasms believed to originate from perivascular myoid cells and are rarely present in ocular structures. We present a rare case of a conjunctival perivascular epithelioid cell tumor that initially presented with recurrent subconjunctival hemorrhage. To our knowledge, this is the first description of a PEComa with a RBM10-TFE3 gene fusion, only previously seen with renal cell carcinoma. Physicians should be aware of this rare condition, its location in the fornix and its presentation as a recurrent subconjunctival hemorrhage.
- 9 September 2022
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 39 (1) , e15-e17
Conjunctival Perivascular Epithelioid Cell Neoplasm With RBM10-TFE3 Fusion Presenting as Recurrent Subconjunctival Hemorrhage
Subconjunctival hemorrhages commonly present to eye care professionals and are frequently regarded as benign self-limited conditions. In selected cases, subconjunctival hemorrhages can be a harbinger of more severe disease. Perivascular epithelioid cell tumors, or PEComas, are rare mesenchymal neoplasms believed to originate from perivascular myoid cells and are rarely present in ocular structures. We present a rare case of a conjunctival perivascular epithelioid cell tumor that initially presented with recurrent subconjunctival hemorrhage. To our knowledge, this is the first description of a PEComa with a RBM10-TFE3 gene fusion, only previously seen with renal cell carcinoma. Physicians should be aware of this rare condition, its location in the fornix and its presentation as a recurrent subconjunctival hemorrhage.
- 6 June 2022
- Published by Taylor & Francis in Orbit
- Vol. 43 (1) , 126-130
Orbital floor reconstruction via autologous radial forearm free flap with palmaris longus tendon
We describe reconstruction of the orbital floor following suprastructure maxillectomy for resection of maxillary squamous cell carcinoma utilizing an osteocutaneous radial forearm free flap and palmaris longus tendon.
- 6 June 2022
- Published by Taylor & Francis in Orbit
- Vol. 43 (1) , 126-130
Orbital floor reconstruction via autologous radial forearm free flap with palmaris longus tendon
We describe reconstruction of the orbital floor following suprastructure maxillectomy for resection of maxillary squamous cell carcinoma utilizing an osteocutaneous radial forearm free flap and palmaris longus tendon.
- 7 July 2021
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 32 (8) , e813-e814
Giant Deep Orbital Dermoid Cyst Presenting in Infancy
Orbital dermoid cysts are benign choristomas that are very common in children and occur most often as a lateral or medial mass associated with the frontozygomatic or frontoethmoidal suture line. The authors present an unusual case of an occult giant deep orbital dermoid cyst in infancy that initially presented with a small, benign appearance and central upper eyelid location on clinical exam. Orbitotomy with complete excision prevented further ocular sequelae in this 11-month-old.
- 7 July 2021
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 32 (8) , e813-e814
Giant Deep Orbital Dermoid Cyst Presenting in Infancy
Orbital dermoid cysts are benign choristomas that are very common in children and occur most often as a lateral or medial mass associated with the frontozygomatic or frontoethmoidal suture line. The authors present an unusual case of an occult giant deep orbital dermoid cyst in infancy that initially presented with a small, benign appearance and central upper eyelid location on clinical exam. Orbitotomy with complete excision prevented further ocular sequelae in this 11-month-old.